As of Sep 11, 2024, the Sarepta Therapeutics stock's PE ratio is 171.19. This results from the current EPS of $0.75 and stock price of $128.39.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Compared to its peer stock GILD, SRPT's PE ratio stands higher.
Stock name | PE ratio | Market cap |
---|---|---|
GILD Gilead Sciences Inc | 97.84 | $103.53B |
SRPT Sarepta Therapeutics Inc | 167.12 | $11.95B |
NVAX Novavax Inc | N/A | $1.91B |
PTCT Ptc Therapeutics Inc | N/A | $2.52B |
BCRX Biocryst Pharmaceuticals Inc | N/A | $1.6B |
ALNY Alnylam Pharmaceuticals Inc | N/A | $33.6B |
RNA Avidity Biosciences Inc | N/A | $4.54B |
INSM INSMED Inc | N/A | $12.7B |
The price to earnings ratio for SRPT stock is 171.19 as of Sep 11, 2024.
A company with a higher PE ratio may indicate that the market has higher growth expectations for the company's future earnings or profitability.
You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Sep 11, 2024), Sarepta Therapeutics's stock price is $128.39. The earnings per share for the trailing twelve months (TTM) ending Jun 2024 is $0.75. Therefore, Sarepta Therapeutics's P/E ratio for today is 171.19. PE RATIO(171.19) = STOCK PRICE($128.39) / TTM EPS($0.75)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.